Last reviewed · How we verify
NCT04064944: CAMPUS
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
Phase 2 trial testing blood purification equipment in Neuromyelitis Optica Spectrum Disorder in 144 participants. Status unknown.
1 August 2023
Quick facts
| Lead sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 144 |
| Start date | 1 September 2019 |
| Primary completion | 1 August 2023 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- blood purification equipment
Conditions studied
- Neuromyelitis Optica Spectrum Disorder — all drugs for Neuromyelitis Optica Spectrum Disorder →
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Who can join
Adults 14 to 65, any sex, with Neuromyelitis Optica Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neuromyelitis optica spectrum disorder (NMOSD) is one common demyelinating disease of the central nervous system in young adults, with high rate of disability and recurrence, and poor natural course, which can cause a serious burden on families and society. To today, there is still a lack of prospective, multi-center, large sample clinical trial evidence for the treatment and prognosis of acute attack of NMOSD patients. This study will conduct a prospective, multi-center, single-blind, randomized controlled clinical trial of acute attacked NMOSD patients in China. The researchers plan to collect 144 NMOSD patients with acute attack in three research centers of Guangzhou (the Third Affiliated Hospital of Sun Yat-sen University, the Zhongshan Ophthalmic Center of Sun Yat-sen University, and the Guangdong 999 Brain hospital), to study the safety and efficacy of immunoadsorption therapy. The subjects will be randomized into immunoadsorption group and plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment. This study is aimed to determine the efficacy and safety of immunoadsorption therapy for acute attack of refractory NMOSD patients, and to provide more sufficient clinical evidence for the therapy selection for acute phase of NMOSD patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E, Correale J. · · 2021 · cited 202× · PMID 34530847 · DOI 10.1186/s12974-021-02249-1 -
Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.
Saitakis G, Chwalisz BK. · · 2022 · cited 9× · PMID 36077167 · DOI 10.3390/ijms23179769 -
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.
Traub J, Husseini L, Weber MS. · · 2021 · cited 9× · PMID 33419217 · DOI 10.3390/ph14010037
Verify or expand the search:
- PubMed search for NCT04064944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuromyelitis Optica Spectrum Disorder
Currently open trials in the same condition.
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
- NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
- NCT05891379 — Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders · recruiting
- NCT06180278 — Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) · Phase 4 · active not recruiting
- NCT05966467 — Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies · recruiting
Other Third Affiliated Hospital, Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
- NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
- NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
- NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
- NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04064944 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
- Last refreshed: 22 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04064944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing